{"id":"NCT02913521","sponsor":"Akorn, Inc.","briefTitle":"Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2016-04","completion":"2016-06","firstPosted":"2016-09-23","resultsPosted":"2021-02-26","lastUpdate":"2021-02-26"},"enrollment":934,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"Diclofenac Sodium Gel 1%","otherNames":[]},{"type":"DRUG","name":"Voltaren Gel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Diclofenac Sodium Gel 1%","type":"EXPERIMENTAL"},{"label":"Voltaren Gel","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee","primaryOutcome":{"measure":"Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference.","timeFrame":"8 weeks","effectByArm":[{"arm":"Diclofenac Sodium Gel 1%","deltaMin":6.8,"sd":2.1},{"arm":"Voltaren Gel","deltaMin":6.7,"sd":2.3},{"arm":"Placebo","deltaMin":5.9,"sd":2.4}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["Estonia","Latvia","Lithuania","Poland","Romania","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":316},"commonTop":["General disorders, muscle/skeletal, and nervous system","application site reaction"]}}